Global Cannabis Applications Corp. (“GCAC” or the “Company”) (GCAC) (CSE:APP, FRA:2FA, OTCQB:FUAPF), a leading developer of innovative data technologies for the cannabis industry, is pleased to announce that it has engaged Crypto Tax & Legal based in Vilnius, Lithuania. Crypto Tax & Legal will represent GCAC and its wholly owned subsidiary GCAC Europe, regarding ICO regulatory compliance and intellectual property, including patent applications, in the European Union.

Crypto Tax & Legal was co-founded by Antanas Guoga, also known as ‘Tony G’, Modestas Kaseliauskas and partner in the firm, Anastasija Plonikova. Guoga is a well know global entrepreneur, tech visionary and angel investor. He serves as a Member of the European Parliament for Lithuania and currently sits on the GCAC ICO Advisory Board. Kaseliauskas served as Director General of the State Tax Inspectorate in Lithuania from 2005-2014 and is responsible for tax compliance for GCAC Europe operations. His extensive EU legal and tax experience are great assets to ensure world class taxation and accounting services. Both Guoga and Kaseliauskas are members of the Bankera ICO Advisory Board. Bankera is one of the largest global ICOs raising approximately $100M USD to date. Plotnikova has worked previously for Europol, Eurojust and EU law firms before stepping into blockchain circles including consultation with the European Union on cryptocurrency and blockchain regulatory adoption. She is also responsible for strategic partnerships to help grow the ETHLend ICO brand which raised more than $23M EUR in just under 72 hours and reached a high of 44 x increase in four weeks. The team also includes legal advisor, Monika Kriunaite who is a leading Lithuanian lawyer for financial compliance and obtaining of IP patent licenses. Dovydas Bernotas, COO and Communications Consultant is member of CTL team as user satisfaction and community manager. Bernotas worked on the Lympo ICO, which raised more than $5M USD during the pre-ICO.

The Crypto Tax & Legal team will be working on the implementation of best world practices of the GCAC Citizen Green initial coin offering.


“I am absolutely delighted to engage CyrptoTax & Legal to represent GCAC’s interests in Europe and beyond,” stated Brad Moore, CEO of GCAC. “In the emerging blockchain and cryptocurrency market it is imperative that GCAC has the best and brightest minds working to ensure success of the Citizen Green ICO. With GCAC now firmly established in the global blockchain community , we are creating relationships across global crypto markets via existing relationship between world class investors, exchanges and companies.”

About Crypto Tax & Legal

Blockchain technology and crypto based activities moved faster than national legal systems, but legislative and regulatory pressure is becoming more prevalent around the world. Even though legal regulation has not yet been established, Crypto Tax & Legal team’s experience allows them to anticipate a few steps forward.

The Crypto Tax & Legal team has deep understanding and passion for crypto currencies and blockchain technology with significant experience to provide first class solution to crypto-based clients. The team unites active people from different successful and well-known projects in the crypto world.

As people and companies in the crypto world face challenges Crypto Tax & Legal can help. Governmental institutions knowledge about crypto is obscure and decisions can be blunt. CTL is helping the crypto industry to setup and regulate best legal business practices working with partners and research centers across the globe.

For more information, please visit: http://cryptotaxlegal.com

About Global Cannabis Applications Corp.

Global Cannabis Applications Corp. is a global leader in designing, developing, marketing, and acquiring innovative data technologies for the cannabis industry. The Citizen Green platform is the world’s first end-to-end – from patient to regulator – medical cannabis data solution. It uses six core technologies: mobile applications, artificial intelligence, reg tech, smart databases, blockchain, which ensures transparency, accountability and fraud free environment, and digital reward tokens, to qualify candidates for clinical studies. These technologies facilitate the proliferation of digital conversations by like-minded people in medical cannabis. Managed by digital and cannabis industry experts, GCAC is focused on viral global expansion by providing the best digital experience in the cannabis market.

For more information about the Company, please visit online at www.cannappscorp.com, or review its profiles www.sedar.com and on the Canadian Securities Exchange’s website (www.thecse.com).

To schedule an interview, please contact:

Bradley Moore

Chief Executive Officer

Telephone: 514-5619091

Email: bmoore@cannappscorp.com

For more information, please contact:

Corporate Communications Canada & Europe

Telephone: 1.855.269.9554

Email: info@cannappscorp.com

www.cannappscorp.com

Corporate Communications United States

Hayden IR

Telephone: 1.917.658.7878

Email: hart@haydenir.com

Forward-Looking Information

This news release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of GCAC. Forward-looking information is based on certain key expectations and assumptions made by the management of GCAC. Although management of the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because GCAC can give no assurance that they will prove to be correct. Forward-looking statements contained in this news release are made as of the date of this news release. GCAC disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy and accuracy of this information.

Click here to connect with Global Cannabis Applications Corp. (GCAC) (CSE:APP, FRA:2FA, OTCQB:FUAPF) and receive an Investors Presentation.

Source: www.thenewswire.com

  • Company surpassed 5,600 patient prescriptions for its medical cannabis products in Colombia . Prescriptions filled increased over 450% in Q3 2020 over Q2 2020
  • Khiron declared a National Strategic Project by the Government of Colombia , simplifying and accelerating administration and processes for the Company in executing strategic projects in Colombia and for export
  • Subsequent to the quarter, the Company completed a bought deal financing on November 26, 2020 , selling 32,200,000 units at a price of $0.45 per unit for aggregate gross proceeds of $14,490,000 CAD
  • Khiron signed partnerships with 15 clinics and health centres in Colombia , extending education and sales reach further across the country
  • As a result of the Company’s Doctor Zerenia TM telehealth platform more than 25% of the Company’s medical cannabis prescriptions came from outside of Bogota , expanding geographic presence of its Colombian clinics
  • Company achieved first sales of High CBD medical cannabis through private pharmacies in Peru . Additional approval received from Peru’s drug regulatory authority for Company’s High THC cannabis, with first prescriptions anticipated in Q1 2021
  • Expanded medical cannabis E-Learning platform to UK market in partnership with Medical Cannabis Clinicians Society (“MCCS”)
  • Entered an exclusive partnership with Rappi SAS, Latin America’s largest home multi-vertical app platform to distribute the Company’s CPG product portfolio, introducing Kuida products to Rappi users across the LatAm region
  • Signed agreement to distribute the Company’s Kuida TM CBD skincare brand through pharmacy, beauty retail and online markets serving the Hong Kong territory, with first orders expected in Q4 2020
  • Prudent cash use of $5 million in Q3 2020, compared with $4 million in Q2 2020, $12 million in Q1 2020 and $10 million in Q4 2019

 Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN ), (OTCQX: KHRNF), ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe announced today its financial results for the quarter ended September 30, 2020 . These filings are available for review on the Company’s SEDAR profile at www.sedar.com All financial information in this press release is reported in Canadian dollars, unless otherwise indicated.

Keep reading... Show less
  • Q3 Systemwide Pro Forma Revenue increased 18% quarter-over-quarter to $22.3 million , 170% year-over-year – Company became cash flow positive from operations in August
  • Company sale leaseback transaction with Innovative Industrial Properties scheduled to close within two weeks. As a result of close, together with proceeds from the recently closed bought deal financing, the Company will have $16 million of cash and $43 million in long-term debt
  • Company is in the process of acquiring acreage to construct up to 210,000 square feet of flowering canopy and supporting manufacturing facility in Cook County, Illinois to exponentially increase capacity in state
  • Initial guidance for 2021 with Systemwide Pro Forma Revenue of $170 -180 million and Adjusted EBITDA of $40 -50 million
  • The Company’s existing projects at maturity represent a long-term revenue and EBITDA opportunity upwards of $650 million and $250 million

4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) today announced its financial results for the third quarter of 2020. All financial information is presented in U.S. dollars unless otherwise indicated.

Third Quarter 2020 Financial Results Highlights

Keep reading... Show less
  • Q3 Systemwide Pro Forma Revenue increased 18% quarter-over-quarter to $22.3 million , 170% year-over-year – Company became cash flow positive from operations in August
  • Company sale leaseback transaction with Innovative Industrial Properties scheduled to close within two weeks. As a result of close, together with proceeds from the recently closed bought deal financing, the Company will have $16 million of cash and $43 million in long-term debt
  • Company is in the process of acquiring acreage to construct up to 210,000 square feet of flowering canopy and supporting manufacturing facility in Cook County, Illinois to exponentially increase capacity in state
  • Initial guidance for 2021 with Systemwide Pro Forma Revenue of $170 -180 million and Adjusted EBITDA of $40 -50 million
  • The Company’s existing projects at maturity represent a long-term revenue and EBITDA opportunity upwards of $650 million and $250 million

4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) today announced its financial results for the third quarter of 2020. All financial information is presented in U.S. dollars unless otherwise indicated.

Third Quarter 2020 Financial Results Highlights

Keep reading... Show less

Shareholders with losses exceeding $50,000 are encouraged to contact the firm

The Law Offices of Frank R. Cruz reminds investors of the upcoming December 1, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Aurora Cannabis, Inc. (“Aurora” or the “Company”) (NYSE: ACB ) securities between February 13, 2020 and September 4, 2020 , inclusive (the “Class Period”).

Keep reading... Show less

Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce the launch of preclinical research studies using psilocybin and N-Acetylcysteine (“NAC”) for the treatment of mild traumatic brain injuryconcussion (“mTBI”) with post-traumatic stress disorder (“PTSD”). The study is in collaboration with a multidisciplinary team of scientists and physicians at the University of Miami Miller School of Medicine under the lead of Michael E. Hoffer, M.D., professor of otolaryngology and neurological surgery.

NAC has been shown to be safe and efficacious in a phase I human clinical study in treating military personnel who had suffered mTBI. The initial research focus is to demonstrate the safety and efficacy of the combination of psilocybin and NAC using broadly accepted rodent models. Final results are expected in 2021. Once this is established, more specific work can examine dose response, medicine uptake, and medicine levels. The research team at the Miller School of Medicine has conducted prior studies involving NAC with mTBI and has a license from the United States Drug Enforcement Administration to conduct research using Schedule I controlled substances, which includes psilocybin.

Keep reading... Show less